WOCKPHARMA2022-10-012022-12-31 WOCKPHARMA2022-10-012022-12-31 WOCKPHARMA2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2022-10-012022-12-31in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2022-10-012022-12-31in-bse-fin:FourOperatingExpenses02Member WOCKPHARMA2022-12-31 WOCKPHARMA2022-10-012022-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2022-10-012022-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2022-10-012022-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2022-10-012022-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2022-04-01 2023-03-31 2023-02-13 2023-02-03 INR Crores Third quarter 11:45:00 14:50:00 2023-02-13 2023-02-13 Not applicable Single segment Pharmaceuticals 2022-10-01 2022-12-31 Unaudited Consolidated 6990000000.00 20000000.00 7010000000.00 1340000000.00 1330000000.00 530000000.00 1500000000.00 830000000.00 660000000.00 1840000000.00 8030000000.00 -1020000000.00 -30000000.00 -1050000000.00 20000000.00 -50000000.00 -30000000.00 0.00 -1020000000.00 0.00 0.00 0.00 0.00 -1020000000.00 1410000000.00 390000000.00 -960000000.00 -60000000.00 480000000.00 -90000000.00 720000000.00 5 -6.62 -6.62 0.00 0.00 -6.62 -6.62 0.00 0.00 0.00 1. For Notes to Consolidated Results, please refer the Notes from the Statement of Consolidated Unaudited Results for the quarter and nine months ended December 31, 2022 as attached which is submitted under Outcome of Board Meeting uploaded today on Stock Exchange. 2. EPS for the quarter and nine months ended December 31, 2022 is not annualised. Single segment 2022-04-01 2022-12-31 Unaudited Consolidated 19730000000.00 1020000000.00 20750000000.00 3820000000.00 3840000000.00 390000000.00 4930000000.00 2260000000.00 1950000000.00 5890000000.00 23080000000.00 -2330000000.00 -1980000000.00 -4310000000.00 100000000.00 -570000000.00 -470000000.00 0.00 -3840000000.00 0.00 0.00 0.00 0.00 -3840000000.00 560000000.00 -3280000000.00 -3520000000.00 -320000000.00 -3090000000.00 -190000000.00 720000000.00 5 -24.42 -24.42 0.00 0.00 -24.42 -24.42 0.00 0.00 0.00 Exchange fluctuation loss / (gain), net 140000000.00 Other expenses 1700000000.00 Exchange fluctuation loss / (gain), net 0.00 Other expenses 5890000000.00 Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) (Continuing operations) -40000000.00 Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) (Continuing operations) -150000000.00 -40000000.00 -150000000.00 0.00 -20000000.00 Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations) 1450000000.00 Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations) 690000000.00 1450000000.00 690000000.00 0.00 0.00